CENTRAL FAX CENTER

Customer No. 28880

SEP 2 0 2005

Confirmation No. 2382

PTO/SB/08A (08-03)

Approved for use through 07/31/2008, OMB 0851-0031
U.S. Pezent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Penerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/734,917 Filing Date December 12, 2003 INFORMATION DISCLOSURE First Named Inventor David James Dooley STATEMENT BY APPLICANT Art Unit 1621 (Use as many sheets as necessary) Examiner Name Deborah D. Carr PC 25870A Attorney Docket Number

	- A			DOCUMENTS	
Examiner Inidats	Cite No.	Document Number Number-Kind Code ² (* Innert)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 6,001,876	12-14-1999	L. Singh, et al	
		us-			
<u></u>		US-		, , , , , , , , , , , , , , , , , , ,	
		US-			
•		US-			<u> </u>
-		US-			
		US-			
		US-			
		US-			<u> </u>
		US-			
		US-			
•••		US-			
		US-			
		∪\$-			
		US-			

Examiner Cite		Foreign Patent Document	GN PATENT DOCU Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ
174440	,,,,	Country Code ³ Number * Kind Code ⁵ (if known)	MM-DD-YYYY	Applicate of Orion Document	Or Relevant Figures Appear	Т
						L
						╄
						╁
						۲.

	· · · · · · · · · · · · · · · · · · ·	
Examiner	· · · · · · · · · · · · · · · · · · ·	Date
Signature		Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Indude copy of this form with next communication to applicant. "Applicant's unique citation designation number (epidents). "See Kinds Codes of USPTO Patent Documents at www.usrto.gov or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the region of the Imperor must procede the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. "Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 nours to complete, including galhering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistence in completing the form, call 1-800-PTO-9199 (1-800-9199) and salect option Z.

RECEIVED CENTRAL FAX CENTER

PATENT PFIZER ANN ARBOR MI



SEP 2 0 2005

PTO/SB/08A (04-03)

Unde	r the Paperwork Reduction Act of 1995, no persons are r		U.S. Patent and Trade	emerk Office; U.S. DEPARTMENT OF COMMERCI stion unless it contains a valid OMB control number
	Paperwork Reduction Act of 1993, no persons are required for form 1448/PYO DRMATION DISCLOSURE		Co	mplete if Known
•			Application Number	10/734,917
IN	FORMATION DISCLOSUS	_	Filing Date	12/12/2003
			First Named Inventor	David J. Dooley
5		I	'Art Unit	1621
•	(Use as many sheets as necessary)		Examiner Name	Unknown ,
Sheet	1 0 2		Altorney Docket Number	PC25870A

Examiner Initiats*	Cité No.	Document Number Number-Kind Code ^{2 (F Innum)}	Publication Date MM-DD-YYYY	Name of Patenties or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 4,024,175	05-17-1977	G. Satzinger, et al.	
-		4,087,544	05-02-1978	G. Satzinger, et al.	
		^{US} - 6,306,910	10-23-2001	L. Magnus, et al.	
		US-		·	
		US-			
		US-			
		Us-			·
		·US-	•		1
	,	us			
		US-			
		US-			
		US-	· · · · · · · · · · · · · · · · · · ·		
		US -			<u> </u>
		US-			
		U\$-	 		
		US-		·	•
		US-	1		
		US-	<u> </u>	<u> </u>	
		US-	 		

	FORE	IGN PATENT DOCL	MENTS		
Cite No.	Foreign Patent Document	Publication Oate	Name of Parentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Passages	Γ
	Country Code ³ "Number ⁴ "Kind Code ⁵ (# Izrówn)	MM-DD-YYYY		Or Relevant Figures Appear	74
 EP	0641330 B1	10-17-2001	R. B. Silverman, et al.		
WÓ	98/17627 A1	04-30-1998	J. S. Bryans, et al.		
	99/21824 A1	05-06-1999	J. S. Bryans, et al.		
wo	00/76958 A2	12-21-2000	T. R. Belliotti, et al.		
 wo	01/28978 A1	04-26-2001	J. S. Bryans, et al.		
WO	01/90052 A1	11-29-2001	J. S. Bryans, et al.		

Signature Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with IMPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional). "See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. "Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). "For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document." (Ond of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. "Applicant is to place a check mark here if English language Transtation is attached.

Trainstation is asserted.

This collection of information is required by 37 CFR 1.97 and 1.93. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on time amount of time you require to complete this form and/or suggestioning the burdon, should be sent to the Child Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313.

If you need essistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

From-

Sep-20-2005 01:43pm

PTC/SB/068 (08-00)
Approved for use through 10/31/2002, CMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid CMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond Complete If Known Substitute for form 14499/PTO 10/734,917 **Application Number** INFORMATION DISCLOSURE Filing Date December 12, 2003 STATEMENT BY APPLICANT First Named Inventor David J. Dooley 1621 Group Art Unit (use as many sheets as necessary) Examiner Name Unknown Sheet of Attorney Dockel Number PC25870A

	I'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	Т
nitiais*	CR6 No.1	Rem (book, magazina, journet, serial, symposium. Calalog, etc.), date, page(a), volume-(saue number(a), publisher, city and/or country where published.	7
		M. V. AMERINGEN et al., "Drugs in development for social anxiety disorder:more to social anxiety than meets the SSRI" Expert Opinion on Investigational Drugs, Ashley Pub. Ltd., London, GB 2000:2215-2231; Vol.9, No. 10	
		A. BARKHUIZEN, "Rational and targeted pharmacologic treatment of fibromyalgia" Rheum Dis Clin N Am 2002;28:261-290	
		R. M. BENNETT, "The rational management of fibromyalgia patients" Rheum Dis Clin N Am 2002; 28: 181-199	Ī
•		D. BUSKILA, "Fibromyalgia, chronic fatigue syndrome and myofacial pain syndrome" Current opinions in Rheumatology 2001;13:117-127	
		B. L. EHRENBERG, et al., "Open-Label Trial of Gabapentin for Periodic Limb Movement Disorder of Sleep", 1997, pp. A278-A279, Vol. 48	
		E. K. GUYMER, et al., "An approach to managing fibromyalgla" Medicine Today 2002:58-59; Vol. 3, No. 12	
		L. J. LEVENTHAL, "Management of fibromyalgia" Ann Intern Med 1999;131:850-8	
•		L. T. MELTZER, et al., "Pregabalin enhances non-rapid eye movement sleep and ecg slow-wave activity in rats" Society for neuro. abstracts 2001:2245 Vol. 27, No. 2	
		I. SELAK, "Pregabalin (Pfizer)" Current opinion in investigational drugs, current drugs, Lond, GB 2001:828-834; Vol. 2, No. 6	
		F. WOLFE, et al., "The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee" Arthritis Rheum 1990; 33:160-72	
		M. B. YUNUS, "A comprehensive medical evaluation of patients with fibromyalgia syndrome" Rheum Dis N Am 2002; 28:201-217	_

Examiner	Date	
,Signature	 Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Petent and Tradement Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, A(8x8)2013, VA 22313

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and net considered. Include copy of this form with next communication to applicant,

⁵ Unique chation designation number. ³ Applicant is to place a check mark here if English language Transistion is attached.

of

From-

Sheet

Signature

Sep-20-2005 01:43pm

	.		
		PTO/\$8/088 10/31/2002, OMB 08	
	,	PIOSBORB	(08-00)
A-mass -		4000 40000 DIAD AD	
Аррготов н	or use introving	10/31/2002. OMH ON	51-0031
U. S. Patent and Trademark (Manuelle Br	DAOTHELT OF ACT	
ev er Lembit win trefatibilit (JIIRG: V.3. レ¢	PARIMENT OF COM	AMERIC
		a verrous ti At AAli	MAINT AME

PC25870A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless R contains a valid QMB control number Complete if Known Substitute for form 1449B/PTO 10/734,917 December 12, 2003 Application Number INFORMATION DISCLOSURE Filing Date David J. Dooley STATEMENT BY APPLICANT First Named Inventor 1621 Group Art Unit (use as many sheets as necessary) Unknown

Examiner Name

Altomey Dockel Number

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite Rem (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-lasue number(e), publisher, city and/or country where published. Initiate* No. D. Garcia-Borreguero et al., "Treatment of restless legs syndrome with gabapentin-A double-blind, cross-over study" Neurology 2002;59:1573-1579 Examiner | Date

Considered

Burdon Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the meets of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Atexandria, VA 22313

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 606. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. *Applicant is to piace a check mark here If English language Translation is attached.

Confirmation No. 2382

Sep-20-2005 01:43pm

PTO/SE/08A (08-03)
Approved for use through 07/31/2008. QMB 0651-0031
U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no nersons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/734,917 Filing Date December 12, 2003 INFORMATION DISCLOSURE Rest Named Inventor David James Dooley, et al. STATEMENT BY APPLICANT Art Unit 1621 (Use as many sheets as necessary) Examiner Name Deborah D. Carr PC25870A Allomey Docket Number

Examinar Initials*	No.	. Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 5,670,539	09-23-1997	Mary Ann Richardson	
		US- 5,919,823	07-06-1999	Mary Ann Richardson	
		US-6,117,908	09-12-2000	Paul L. R. Andrews, et al.	
		US-6,127,418	10-03-2000	Lionel Bueno, et al.	
•		US-6,248,363 B1	06-19-2001	Mahesh V. Patel, et al.	
		^{US-} 6,309,663 B1	10-30-2001	Mahesh V. Patel, et al.	
		US- 6,310,098 B1	10-30-2001	Thomas J. Guttuso, Jr.	·
		US- 6,372,792 B1	04-16-2002	Guy Chouinard	
	•	US-2002-0035057 A1	03-21-2002	Virginia Pact Richter, et al.	
. '		US-2002-0037926 A1	03-28-2002	Nancy C. Lan	
		US-2002/0072538 A1	06-13-2002	Bertrand L. Chenard, et al.	
. ,		US-2002/0099013 A1	07-25-2002	Thomas Piccariello, et al.	
		US-20020099092 A1	07-25-2002	David Clive Blakemore, et al.	
		US-2002/0165246 A1	11-07-2002	Andrew Holman	
		US- 2003/0144214 A1	07-31-2003	David Clive Blakemore, et al.	
		US-			
		u\$-			
	\neg	US-		•	
		US-			1

			IGN PATENT DOC	JMENTS		
Examiner Initials*	Cite No.	Foreign Palent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Passages	Π
	'	Country Code ² "Number ⁴ "Kind Code ⁸ (# forown)	MM-DD-YYYY		Or Relevant Figures Appoor	7
		WO 01/13904 A2	03-01-2001	Ortho-Meneil Pharmaceut		
		WO 01/45714 A2	06-28-2001	Glaxo Group Limited		
		WO 02/34237 A1	05-02-2002	New River Pharmeceutical	s Inc.	\square
		WO 03/061656 A1	07-31-2003	Endo Pharmaceuticals Inc.	•	
		DE 198 02 327 A1	07-29-1999	Godecke AG		

Examine dicO Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional). "See Kinds Codes of USPTO Patent Documents at www.uspite.gov or MPEP 801.04. "Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the temperor must precede the serial number of the patient document. "And of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. "Applicant is to place a check mark here if English language Translation is attached.

Transation is statched.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to the (and by the USPTO to process) an appRosition. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Three wit vary depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for the burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commitseloner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.